Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novabay Pharmaceuticals (NY: NBY )

0.7198 +0.0108 (+1.52%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novabay Pharmaceuticals

< Previous 1 2 3 4 Next >
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.